Delisting risk
Curis (CRIS)
Develops emavusertib combinations for primary central nervous system lymphoma and chronic lymphocytic leukemia.
$1.40
Pre-market+0.01 (+0.43%)
At close$1.39(−2.11%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions42 holders · as of Mar 31, 2026 | 40.45% | 788.3K shares | |
| Insiders6 holders · as of Apr 1, 2026 | 1.02% | 20.0K shares | |
| Otherremainder | 58.53% | 1.14M shares |
1.95M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
42 holders · 15.77M shares · 12 new positions · 26 increased · 6 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 3.80M | 195.10% | +2.67M | May 14, 2026 |
| Stonepine Capital Management, LLC | 3.73M | 191.20% | +3.67M | May 14, 2026 |
| Nantahala Capital Management, LLC | 2.00M | 102.62% | +2.00Mnew | May 15, 2026 |
| Sphera Funds Management Ltd. | 1.99M | 102.36% | +1.99Mnew | May 15, 2026 |
| Cable Car Capital LLC | 1.33M | 68.41% | +1.33Mnew | May 15, 2026 |
| Dauntless Investment Group, LLC | 658.7K | 33.80% | +658.7Knew | May 14, 2026 |
| Vanguard Capital Management LLC | 374.3K | 19.21% | +374.3Knew | May 15, 2026 |
| Renaissance Technologies LLC | 366.7K | 18.82% | +125.8K | May 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 9.99% | 13G | Apr 24, 2026 ↗ | |
| Armistice Capital, LLC | 9.99% | 13G | Aug 14, 2025 ↗ | |
| Thomas A. Satterfield, Jr. | 9.90% | 13G | May 14, 2026 ↗ | |
| Stonepine Capital Management, LLC | 9.90% | 13G | Mar 27, 2026 ↗ | |
| Bleichroeder LP | 9.90% | 13G | Mar 31, 2025 ↗ | |
| Nantahala Capital Partners Limited Partnership | 6.98% | 13G | Apr 7, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 31, 2026 | Kenneth I. Kaitindirector | Purchase | 10,000 | $0.5487 | 11,407 |
CongressHouse and Senate disclosures
Not reported.
